# Metagenomi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/metagenomi

- Industry: Biotechnology
- Headquarters: Emeryville, US
- Website: www.metagenomi.co/
- Total disclosed funding: $376M
- Latest round: Series B (Jan 5, 2023)
- Investors on record: 23

## About

Based in California, US, and founded in 2018, Metagenomi, Inc., operates as a gene-editing system that provides analytics solutions using machine learning for treating genetic diseases. The company was founded by Brian Thomas and Jillian Banfield. In April 2021, Metagenomi, Inc., raised USD 10 million in series A funding from RA Capital, HOF Capital, Sozo Ventures, and other investors. In February 2024, Metagenomi, Inc., raised USD 93.75 million in an IPO, selling 6.25 million shares at USD 15 per share, at the expected USD 15-17 range, on the Nasdaq Global Select Market under the ticker symbol "MGX".

The company provides a CRISPR-based system that focuses on the development and research of cell and gene therapies for genetic diseases such as Cystic fibrosis, Sickle-cell anemia, and Marfan syndrome.

Metagenomi, Inc. plans to expand its team and development of its therapeutic pipeline.

## Funding rounds

- Series B, Jan 5, 2023, $100M — Novo Holdings, Moderna, Inc., Farallon Capital Management, Leaps by Bayer, Catalio Capital Management, Deep Track Capital, PFM Health Sciences, SymBiosis Capital Management
- Series B, Jan 25, 2022, $175M — Frazier Healthcare Partners, Novo Holdings, Marshall Wace, Millennium Management, Bristol-Myers Squibb Company, Pura Vida Investments, RA Capital Management, Moderna, Inc., Farallon Capital Management, Eventide Asset Management, Surveyor Capital, Leaps by Bayer, Irving Investors, Humboldt Fund, Deep Track Capital, PFM Health Sciences
- Series A, Mar 15, 2021, $10M — InCube Ventures, RA Capital Management, Sozo Ventures, HOF Capital, Agent Capital, Leaps by Bayer, Humboldt Fund
- Series A, Nov 12, 2020, $65M — InCube Ventures, Sozo Ventures, HOF Capital, Agent Capital, Leaps by Bayer, Humboldt Fund
- Series A, Aug 13, 2019, $26M — InCube Ventures, Bayer AG, HOF Capital
- Seed, Feb 28, 2019 — InCube Ventures

## Investors

- InCube Ventures — Seed, Series A
- Bayer AG — Series A
- HOF Capital (https://capitalatlas.ai/funds/hof-capital) — Series A
- Sozo Ventures (https://capitalatlas.ai/funds/sozo-ventures) — Series A
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A, Series B
- Humboldt Fund (https://capitalatlas.ai/funds/humboldt-fund) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B
- Novo Holdings — Series B
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series B
- Millennium Management — Series B
- Bristol-Myers Squibb Company — Series B
- Pura Vida Investments (https://capitalatlas.ai/funds/pura-vida-investments) — Series B
- Moderna, Inc. — Series B
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series B
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series B
- Surveyor Capital — Series B
- Irving Investors (https://capitalatlas.ai/funds/irving-investors) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B
- PFM Health Sciences (https://capitalatlas.ai/funds/pfm-health-sciences) — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B
- SymBiosis Capital Management (https://capitalatlas.ai/funds/symbiosis-capital-management) — Series B